View in EDS

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.

Saved in:
Bibliographic Details
Title: Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Authors: Galsky, Matthew D (AUTHOR), Arija, José Ángel Arranz (AUTHOR), Bamias, Aristotelis (AUTHOR), Davis, Ian D (AUTHOR), De Santis, Maria (AUTHOR), Kikuchi, Eiji (AUTHOR), Garcia-Del-Muro, Xavier (AUTHOR), De Giorgi, Ugo (AUTHOR), Mencinger, Marina (AUTHOR), Izumi, Kouji (AUTHOR), Panni, Stefano (AUTHOR), Gumus, Mahmut (AUTHOR), Özgüroğlu, Mustafa (AUTHOR), Kalebasty, Arash Rezazadeh (AUTHOR), Park, Se Hoon (AUTHOR), Alekseev, Boris (AUTHOR), Schutz, Fabio A (AUTHOR), Li, Jian-Ri (AUTHOR), Ye, Dingwei (AUTHOR), Vogelzang, Nicholas J (AUTHOR)
Source: Lancet. 5/16/2020, Vol. 395 Issue 10236, p1547-1557. 11p.
Subjects: Cancer chemotherapy, Cancer-related mortality, Research, Carboplatin, Intravenous therapy, Clinical trials, Research methodology, Antineoplastic agents, Monoclonal antibodies, Evaluation research, Medical cooperation, Transitional cell carcinoma, Urinary organs, Comparative studies, Randomized controlled trials, Cisplatin, Kaplan-Meier estimator, Proportional hazards models
Abstract: Background: Atezolizumab can induce sustained responses in metastatic urothelial carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab with or without platinum-based chemotherapy versus placebo plus platinum-based chemotherapy in first-line metastatic urothelial carcinoma.Methods: In this multicentre, phase 3, randomised trial, untreated patients aged 18 years or older with locally advanced or metastatic urothelial carcinoma, from 221 sites in 35 countries, were randomly assigned to receive atezolizumab plus platinum-based chemotherapy (group A), atezolizumab monotherapy (group B), or placebo plus platinum-based chemotherapy (group C). Patients received 21-day cycles of gemcitabine (1000 mg/m2 body surface area, administered intravenously on days 1 and 8 of each cycle), plus either carboplatin (area under the curve of 4·5 mg/mL per min administered intravenously) or cisplatin (70 mg/m2 body surface area administered intravenously) on day 1 of each cycle with either atezolizumab (1200 mg administered intravenously on day 1 of each cycle) or placebo. Group B patients received 1200 mg atezolizumab, administered intravenously on day 1 of each 21-day cycle. The co-primary efficacy endpoints for the intention-to-treat population were investigator-assessed Response Evaluation Criteria in Solid Tumours 1.1 progression-free survival and overall survival (group A vs group C) and overall survival (group B vs group C), which was to be formally tested only if overall survival was positive for group A versus group C. The trial is registered with ClinicalTrials.gov, NCT02807636.Findings: Between July 15, 2016, and July 20, 2018, we enrolled 1213 patients. 451 (37%) were randomly assigned to group A, 362 (30%) to group B, and 400 (33%) to group C. Median follow-up for survival was 11·8 months (IQR 6·1-17·2) for all patients. At the time of final progression-free survival analysis and interim overall survival analysis (May 31, 2019), median progression-free survival in the intention-to-treat population was 8·2 months (95% CI 6·5-8·3) in group A and 6·3 months (6·2-7·0) in group C (stratified hazard ratio [HR] 0·82, 95% CI 0·70-0·96; one-sided p=0·007). Median overall survival was 16·0 months (13·9-18·9) in group A and 13·4 months (12·0-15·2) in group C (0·83, 0·69-1·00; one-sided p=0·027). Median overall survival was 15·7 months (13·1-17·8) for group B and 13·1 months (11·7-15·1) for group C (1·02, 0·83-1·24). Adverse events that led to withdrawal of any agent occurred in 156 (34%) patients in group A, 22 (6%) patients in group B, and 132 (34%) patients in group C. 50 (11%) patients in group A, 21 (6%) patients in group B, and 27 (7%) patients in group C had adverse events that led to discontinuation of atezolizumab or placebo.Interpretation: Addition of atezolizumab to platinum-based chemotherapy as first-line treatment prolonged progression-free survival in patients with metastatic urothelial carcinoma. The safety profile of the combination was consistent with that observed with the individual agents. These results support the use of atezolizumab plus platinum-based chemotherapy as a potential first-line treatment option for metastatic urothelial carcinoma.Funding: F Hoffmann-La Roche and Genentech. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 143484098
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Galsky%2C+Matthew+D%22">Galsky, Matthew D</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Arija%2C+José+Ángel+Arranz%22">Arija, José Ángel Arranz</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bamias%2C+Aristotelis%22">Bamias, Aristotelis</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Davis%2C+Ian+D%22">Davis, Ian D</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22De+Santis%2C+Maria%22">De Santis, Maria</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kikuchi%2C+Eiji%22">Kikuchi, Eiji</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Garcia-Del-Muro%2C+Xavier%22">Garcia-Del-Muro, Xavier</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22De+Giorgi%2C+Ugo%22">De Giorgi, Ugo</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mencinger%2C+Marina%22">Mencinger, Marina</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Izumi%2C+Kouji%22">Izumi, Kouji</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Panni%2C+Stefano%22">Panni, Stefano</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gumus%2C+Mahmut%22">Gumus, Mahmut</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Özgüroğlu%2C+Mustafa%22">Özgüroğlu, Mustafa</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kalebasty%2C+Arash+Rezazadeh%22">Kalebasty, Arash Rezazadeh</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Park%2C+Se+Hoon%22">Park, Se Hoon</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Alekseev%2C+Boris%22">Alekseev, Boris</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Schutz%2C+Fabio+A%22">Schutz, Fabio A</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Li%2C+Jian-Ri%22">Li, Jian-Ri</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ye%2C+Dingwei%22">Ye, Dingwei</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vogelzang%2C+Nicholas+J%22">Vogelzang, Nicholas J</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 5/16/2020, Vol. 395 Issue 10236, p1547-1557. 11p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Cancer+chemotherapy%22">Cancer chemotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer-related+mortality%22">Cancer-related mortality</searchLink><br /><searchLink fieldCode="DE" term="%22Research%22">Research</searchLink><br /><searchLink fieldCode="DE" term="%22Carboplatin%22">Carboplatin</searchLink><br /><searchLink fieldCode="DE" term="%22Intravenous+therapy%22">Intravenous therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+trials%22">Clinical trials</searchLink><br /><searchLink fieldCode="DE" term="%22Research+methodology%22">Research methodology</searchLink><br /><searchLink fieldCode="DE" term="%22Antineoplastic+agents%22">Antineoplastic agents</searchLink><br /><searchLink fieldCode="DE" term="%22Monoclonal+antibodies%22">Monoclonal antibodies</searchLink><br /><searchLink fieldCode="DE" term="%22Evaluation+research%22">Evaluation research</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+cooperation%22">Medical cooperation</searchLink><br /><searchLink fieldCode="DE" term="%22Transitional+cell+carcinoma%22">Transitional cell carcinoma</searchLink><br /><searchLink fieldCode="DE" term="%22Urinary+organs%22">Urinary organs</searchLink><br /><searchLink fieldCode="DE" term="%22Comparative+studies%22">Comparative studies</searchLink><br /><searchLink fieldCode="DE" term="%22Randomized+controlled+trials%22">Randomized controlled trials</searchLink><br /><searchLink fieldCode="DE" term="%22Cisplatin%22">Cisplatin</searchLink><br /><searchLink fieldCode="DE" term="%22Kaplan-Meier+estimator%22">Kaplan-Meier estimator</searchLink><br /><searchLink fieldCode="DE" term="%22Proportional+hazards+models%22">Proportional hazards models</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>Atezolizumab can induce sustained responses in metastatic urothelial carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab with or without platinum-based chemotherapy versus placebo plus platinum-based chemotherapy in first-line metastatic urothelial carcinoma.<bold>Methods: </bold>In this multicentre, phase 3, randomised trial, untreated patients aged 18 years or older with locally advanced or metastatic urothelial carcinoma, from 221 sites in 35 countries, were randomly assigned to receive atezolizumab plus platinum-based chemotherapy (group A), atezolizumab monotherapy (group B), or placebo plus platinum-based chemotherapy (group C). Patients received 21-day cycles of gemcitabine (1000 mg/m2 body surface area, administered intravenously on days 1 and 8 of each cycle), plus either carboplatin (area under the curve of 4·5 mg/mL per min administered intravenously) or cisplatin (70 mg/m2 body surface area administered intravenously) on day 1 of each cycle with either atezolizumab (1200 mg administered intravenously on day 1 of each cycle) or placebo. Group B patients received 1200 mg atezolizumab, administered intravenously on day 1 of each 21-day cycle. The co-primary efficacy endpoints for the intention-to-treat population were investigator-assessed Response Evaluation Criteria in Solid Tumours 1.1 progression-free survival and overall survival (group A vs group C) and overall survival (group B vs group C), which was to be formally tested only if overall survival was positive for group A versus group C. The trial is registered with ClinicalTrials.gov, NCT02807636.<bold>Findings: </bold>Between July 15, 2016, and July 20, 2018, we enrolled 1213 patients. 451 (37%) were randomly assigned to group A, 362 (30%) to group B, and 400 (33%) to group C. Median follow-up for survival was 11·8 months (IQR 6·1-17·2) for all patients. At the time of final progression-free survival analysis and interim overall survival analysis (May 31, 2019), median progression-free survival in the intention-to-treat population was 8·2 months (95% CI 6·5-8·3) in group A and 6·3 months (6·2-7·0) in group C (stratified hazard ratio [HR] 0·82, 95% CI 0·70-0·96; one-sided p=0·007). Median overall survival was 16·0 months (13·9-18·9) in group A and 13·4 months (12·0-15·2) in group C (0·83, 0·69-1·00; one-sided p=0·027). Median overall survival was 15·7 months (13·1-17·8) for group B and 13·1 months (11·7-15·1) for group C (1·02, 0·83-1·24). Adverse events that led to withdrawal of any agent occurred in 156 (34%) patients in group A, 22 (6%) patients in group B, and 132 (34%) patients in group C. 50 (11%) patients in group A, 21 (6%) patients in group B, and 27 (7%) patients in group C had adverse events that led to discontinuation of atezolizumab or placebo.<bold>Interpretation: </bold>Addition of atezolizumab to platinum-based chemotherapy as first-line treatment prolonged progression-free survival in patients with metastatic urothelial carcinoma. The safety profile of the combination was consistent with that observed with the individual agents. These results support the use of atezolizumab plus platinum-based chemotherapy as a potential first-line treatment option for metastatic urothelial carcinoma.<bold>Funding: </bold>F Hoffmann-La Roche and Genentech. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=143484098
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(20)30230-0
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 11
        StartPage: 1547
    Subjects:
      – SubjectFull: Cancer chemotherapy
        Type: general
      – SubjectFull: Cancer-related mortality
        Type: general
      – SubjectFull: Research
        Type: general
      – SubjectFull: Carboplatin
        Type: general
      – SubjectFull: Intravenous therapy
        Type: general
      – SubjectFull: Clinical trials
        Type: general
      – SubjectFull: Research methodology
        Type: general
      – SubjectFull: Antineoplastic agents
        Type: general
      – SubjectFull: Monoclonal antibodies
        Type: general
      – SubjectFull: Evaluation research
        Type: general
      – SubjectFull: Medical cooperation
        Type: general
      – SubjectFull: Transitional cell carcinoma
        Type: general
      – SubjectFull: Urinary organs
        Type: general
      – SubjectFull: Comparative studies
        Type: general
      – SubjectFull: Randomized controlled trials
        Type: general
      – SubjectFull: Cisplatin
        Type: general
      – SubjectFull: Kaplan-Meier estimator
        Type: general
      – SubjectFull: Proportional hazards models
        Type: general
    Titles:
      – TitleFull: Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Galsky, Matthew D
      – PersonEntity:
          Name:
            NameFull: Arija, José Ángel Arranz
      – PersonEntity:
          Name:
            NameFull: Bamias, Aristotelis
      – PersonEntity:
          Name:
            NameFull: Davis, Ian D
      – PersonEntity:
          Name:
            NameFull: De Santis, Maria
      – PersonEntity:
          Name:
            NameFull: Kikuchi, Eiji
      – PersonEntity:
          Name:
            NameFull: Garcia-Del-Muro, Xavier
      – PersonEntity:
          Name:
            NameFull: De Giorgi, Ugo
      – PersonEntity:
          Name:
            NameFull: Mencinger, Marina
      – PersonEntity:
          Name:
            NameFull: Izumi, Kouji
      – PersonEntity:
          Name:
            NameFull: Panni, Stefano
      – PersonEntity:
          Name:
            NameFull: Gumus, Mahmut
      – PersonEntity:
          Name:
            NameFull: Özgüroğlu, Mustafa
      – PersonEntity:
          Name:
            NameFull: Kalebasty, Arash Rezazadeh
      – PersonEntity:
          Name:
            NameFull: Park, Se Hoon
      – PersonEntity:
          Name:
            NameFull: Alekseev, Boris
      – PersonEntity:
          Name:
            NameFull: Schutz, Fabio A
      – PersonEntity:
          Name:
            NameFull: Li, Jian-Ri
      – PersonEntity:
          Name:
            NameFull: Ye, Dingwei
      – PersonEntity:
          Name:
            NameFull: Vogelzang, Nicholas J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 16
              M: 05
              Text: 5/16/2020
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 395
            – Type: issue
              Value: 10236
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1